<h4>Background</h4>Osimertinib is the standard therapy for patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) harbouring sensitising epidermal growth factor receptor (EGFR) mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.